Literature DB >> 11472739

Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.

E Wong1, J Q Huang, P Tagari, D Riendeau.   

Abstract

Prostacyclin (PGI(2)) is a potent vasodilator and inhibitor of platelet aggregation that is produced by prostacyclin synthase via the cyclooxygenase (COX) pathway of arachidonic acid metabolism. We investigated the potential role of COX-2 in the production of vasoactive prostanoids by aortic tissue in a rabbit model of dietary cholesterol-induced atherosclerosis. COX-1 was detected as the major isoform by immunoblot analysis in extracts from aortas of normal and 8 week cholesterol-fed animals with COX-2 being induced in atherosclerotic plaques from cholesterol-fed animals. Aortic tissue from cholesterol-fed animals showed decreased levels of basal 6-keto-PGF(1 alpha) and PGE(2) production as compared to the normal controls but showed no difference with respect to their ability to synthesize these prostanoids in response to exogenous arachidonic acid. The highly selective COX-2 inhibitors rofecoxib and the furanone DFP at concentrations of up to 10 micromol/l had no effect on the arachidonic acid-dependent production of 6-keto-PGF(1 alpha), in contrast to indomethacin, which caused a complete inhibition at 0.5 micromol/l. Celecoxib caused a significant inhibition of 6-keto-PGF(1 alpha) at 10 micromol/l but had little effect when the dose was lowered to 1 micromol/l. Similar effects of these inhibitors were observed with respect to the production of PGE(2) and no major difference was observed between aortic tissues from normal and cholesterol-fed animals with regard to inhibitor sensitivity. These results indicate that in a rabbit model of early stage cardiovascular disease, the basal production of 6-keto-PGF(1 alpha) and PGE(2) by aortic tissue is decreased. Furthermore, COX-2 expression is induced in atherosclerotic plaques and may play a role in altering localized synthesis of prostanoids in these lesions but does not appear to significantly impact the arachidonic acid-dependent prostacylin production of aortic tissues, which is largely mediated by COX-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472739     DOI: 10.1016/s0021-9150(00)00756-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

2.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 3.  Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.

Authors:  Francesco Cipollone; Maria Luigia Fazia
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

4.  COX-1(+/-)COX-2(-/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1.

Authors:  T E Riehl; L He; L Zheng; S Greco; D M Tollefsen; W F Stenson
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

5.  Regulation of the expression of cyclooxygenases and production of prostaglandin I₂ and E₂ in human coronary artery endothelial cells by curcumin.

Authors:  X Tan; E M Poulose; V V Raveendran; B-T Zhu; D J Stechschulte; K N Dileepan
Journal:  J Physiol Pharmacol       Date:  2011-02       Impact factor: 3.011

Review 6.  Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Authors:  Timothy D Warner; Sven Nylander; Carl Whatling
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

7.  Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.

Authors:  Edwin S L Chan; Hongwei Zhang; Patricia Fernandez; Sari D Edelman; Michael H Pillinger; Louis Ragolia; Thomas Palaia; Steven Carsons; Allison B Reiss
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks.

Authors:  Nicholas S Kirkby; Martina H Lundberg; William R Wright; Timothy D Warner; Mark J Paul-Clark; Jane A Mitchell
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

9.  Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs.

Authors:  Blerina Ahmetaj-Shala; Nicholas S Kirkby; Rebecca Knowles; Malak Al'Yamani; Sarah Mazi; Zhen Wang; Arthur T Tucker; Louise Mackenzie; Paul C J Armstrong; Rolf M Nüsing; James A P Tomlinson; Timothy D Warner; James Leiper; Jane A Mitchell
Journal:  Circulation       Date:  2014-12-09       Impact factor: 29.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.